Trials / Completed
CompletedNCT01901107
Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphataemia Receiving Hemodialysis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,078 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this survey is to evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
Detailed description
Bixalomer is administered at initial oral dosage of 500 mg three times a day just before a meal. The dosage can be adjusted based on symptoms and serum phosphorus level.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Kiklin capsules | oral |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2013-07-17
- Last updated
- 2017-01-27
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01901107. Inclusion in this directory is not an endorsement.